Eli Lilly and Company (NYSE:LLY) Shares Sold by Horizon Investment Services LLC

Horizon Investment Services LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 21.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,444 shares of the company’s stock after selling 392 shares during the quarter. Horizon Investment Services LLC’s holdings in Eli Lilly and Company were worth $1,115,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vertex Planning Partners LLC lifted its holdings in shares of Eli Lilly and Company by 21.6% in the fourth quarter. Vertex Planning Partners LLC now owns 597 shares of the company’s stock valued at $461,000 after buying an additional 106 shares during the period. Orion Portfolio Solutions LLC lifted its position in Eli Lilly and Company by 13.9% in the 4th quarter. Orion Portfolio Solutions LLC now owns 43,569 shares of the company’s stock worth $33,635,000 after buying an additional 5,327 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Eli Lilly and Company by 6.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 662,370 shares of the company’s stock valued at $511,350,000 after buying an additional 40,778 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its stake in shares of Eli Lilly and Company by 2.6% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 352,620 shares of the company’s stock worth $272,223,000 after purchasing an additional 9,034 shares during the last quarter. Finally, Broadway Wealth Solutions Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth $363,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $820.30 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a market cap of $777.78 billion, a P/E ratio of 70.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The stock’s 50-day moving average price is $844.31 and its two-hundred day moving average price is $836.82. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its board has authorized a stock buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a report on Thursday, January 16th. Bank of America reissued a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Finally, Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.